Advertisement

Topics

Luxturna cleared for sale in Europe, but payer support uncertain

02:01 EST 26 Nov 2018 | BioPharmaDive

Spark and commercialization partner Novartis now face the battle of getting the pricey gene therapy covered in Europe. 

Original Article: Luxturna cleared for sale in Europe, but payer support uncertain

NEXT ARTICLE

More From BioPortfolio on "Luxturna cleared for sale in Europe, but payer support uncertain"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...